Business
Denali Therapeutics Announces Board and Executive Leadership Updates
SOUTH SAN FRANCISCO, Calif., Nov. 06, 2025 (GLOBE NEWSWIRE) -- Denali Therapeutics Inc. (NASDAQ: DNLI) today announced updates to its Board of Directors and
About this update from Denali Therapeutics Inc.
[{"type":"text","content":"SOUTH SAN FRANCISCO, Calif., Nov. 06, 2025 (GLOBE NEWSWIRE) -- Denali Therapeutics Inc. (NASDAQ: DNLI) today announced updates to its Board of Directors and executive leadership team. Tim Van Hauwermeiren has been appointed to Denali’s Board of Directors. Mr. Van Hauwermeiren is co-founder and Chief Executive Officer of argenx. Carole Ho, M.D., who has served as Denali’s Chief Medical Officer and Head of Development since 2015, will be departing to join Eli Lilly and Company as Executive Vice President, and President of Lilly Neuroscience. Peter Chin, M.D., is assuming the role of Acting Chief Medical Officer and Head of Development at Denali. Dr. Chin is a neurologist and joined Denali in 2019, most recently serving as Senior Vice President of the Enzyme TransportVehicle™ (ETV) Franchise and Late-Stage Clinical Development. “We are thrilled to welcome Tim to our Board of Directors. His rare combination of scientific insight, commercial acumen and leadership experience in successfully scaling a biotech organization from founding to commercial success will be invaluable as we continue to grow and advance towards the potential approval and launch of our first product,” said Ryan Watts, Ph.D., Chief Executive Officer of Denali Therapeutics. “I also want to express our deep gratitude to Carole for her many contributions over the past decade. In collaboration with Carole, Peter has played a key role in building our clinical development organization and leading the filing of our first Biologics License Application for tividenofusp alfa for Hunter syndrome. We are confident that Peter’s proven expertise will ensure a seamless transition and continued focus on delivering transformative medicines to patients.” “I am honored to join Denali as the team prepares for commercialization of its first medicine and advances its TransportVehicle (TV) platform, which has the potential to transform the way we deliver biologics to the entire body, including the brain,” said Mr. Van Hauwermeiren. “I have seen firsthand how strategic focus, operational excellence and a patient-centric mindset enables a successful transition from a clinical-stage to a commercial-stage company. I look forward to working with the Denali leadership team and Board to help unlock the full potential of the TV platform.” “It has been a privilege to work alongside the talented ...